Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM)

P. M. Voorhees; R. F. Manges; P. Sonneveld; G. Somlo; S. Jagannath; S. Zweegman; M. Munteanu; J. T. Vermeulen; H. Xie; R. Z. Orlowski

Journal Article

Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM)

Voorhees P
Manges R
Sonneveld P
et al.

Journal of Clinical Oncology (2008) 26(15_suppl) 8593-8593

DOI: 10.1200/jco.2008.26.15_suppl.8593

N/ACitations

N/AReaders

Get full text

Cite

CITATION STYLE

APA

Voorhees, P. M., Manges, R. F., Sonneveld, P., Somlo, G., Jagannath, S., Zweegman, S., … Orlowski, R. Z. (2008). Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology, 26(15_suppl), 8593–8593. https://doi.org/10.1200/jco.2008.26.15_suppl.8593

Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM)

Cite

Register to see more suggestions